Sorry, you need to enable JavaScript to visit this website.

DHHS Guidelines: Rapid Initiation | SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) HCP

DHHS Guidelines: Rapid Initiation

Selected Sections From the DHHS Guidelines: Rapid Initiation


Boosted DRV with FTC or 3TC plus TAF or TDF
Blue shield icon
  • Boosted DRV has a high barrier to resistance and a low rate of treatment-emergent resistance
DTG with FTC or 3TC plus TDF or TAF
Woman icon
  • DTG/3TC is not recommended in rapid initiation
Question mark icon
  • Clinical data and experience defining the BIC barrier to resistance are relatively limited at this time
  • Because of insufficient data in pregnancy, BIC/TAF/FTC should not be used in people who are pregnant

*A sample for genotypic testing should be sent before initiation of ART.1

DRV/c is not recommended for use in pregnancy.1,2

3TC=lamivudine; ART=antiretroviral therapy; BIC=bictegravir; DHHS=Department of Health and Human Services; DRV=darunavir; DRV/c=darunavir/cobicistat; DTG=dolutegravir; FTC=emtricitabine; TAF=tenofovir alafenamide; TDF=tenofovir disoproxil fumarate.

References: 1. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Updated January 20, 2022. Accessed March 8, 2022. 2. SYMTUZA® [package insert]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP.

You may be interested in: